Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Arab Healthcare 1996: the International Hospital, Medical Equipment and Services Exhibition (United Arab Emirates) December 1996:

This article was originally published in Clinica

Executive Summary

Arab Healthcare '96: the International Hospital, Medical Equipment and Services Exhibition will take place on December 10th-13th, 1996, at the Dubai World Trade Centre, UAE. It is being organised by IIR Exhibitions in collaboration with the Department of Health & Medical Services, Government of Dubai, and in conjunction with the Emirates Medical Association. Further details are available from either: IIR Holdings, Al Seddiqi Building, PO Box 21743, Dubai, UAE. Tel: +971 (4) 512777. Fax: +971 (4) 522 834; or: IIR Exhibitions, Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK. Tel: +44 (171) 344 3888. Fax: +44 (171) 344 3829.

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel